The FDA has approved Heidelberg Engineering’s optical coherence tomography angiography module (OCTA), the company said today. The module is available for new and existing Spectralis upgradeable diagnostic imaging devices used to manage diabetic retinopathy, age-related macular degeneration and other macular diseases.
OCTA is a noninvasive imaging technique that provides three-dimensional visualization of perfused ocular vasculature. Structural OCT uses light waves to take cross-section pictures of the retina, allowing the ophthalmologist to map and measure the thickness of each of the retina’s distinctive layers. Combined with dye-based angiography, the OCTA technology is designed to give clinicians a more comprehensive understanding of ocular abnormalities.
